

=> fil hcaplu
 FILE 'HCAPLUS' ENTERED AT 16:05:50 ON 25 NOV 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Nov 2002 VOL 137 ISS 22
 FILE LAST UPDATED: 24 Nov 2002 (20021124/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d stat que
 L7

68 SEA FILE=REGISTRY (10238-21-8/BI OR 103775-10-6/BI OR 109214-55-3/BI OR 110703-94-1/BI OR 111025-46-8/BI OR 111223-26-8/BI OR 11128-99-7/BI OR 112733-06-9/BI OR 112808-22-7/BI OR 114798-26-4/BI OR 1156-19-0/BI OR 122320-73-4/BI OR 129688-50-2/BI OR 134523-00-5/BI OR 135062-02-1/BI OR 136087-85-9/BI OR 137862-53-4/BI OR 138402-11-6/BI OR 139481-59-7/BI OR 145599-86-6/BI OR 147098-20-2/BI OR 147254-64-6/BI OR 161600-01-7/BI OR 21187-98-4/BI OR 251454-45-2/BI OR 251565-85-2/BI OR 287714-41-4/BI OR 29094-61-9/BI OR 33342-05-1/BI OR 56180-94-0/BI OR 62571-86-2/B I OR 657-24-9/BI OR 68367-52-2/BI OR 72702-95-5/BI OR 74258-86-9/BI OR 75847-73-3/BI OR 76547-98-3/BI OR 79902-63-9/BI OR 80830-42-8/BI OR 80876-01-3/BI OR 81045-50-3/BI OR 81093-37-0/B I OR 81872-10-8/BI OR 82159-09-9/BI OR 82768-85-2/BI OR 82834-16-0/BI OR 82924-03-6/BI OR 82964-04-3/BI OR 83435-66-9/B I OR 83602-05-5/BI OR 83647-97-6/BI OR 85441-61-8/BI OR 86541-75-5/BI OR 86541-78-8/BI OR 87333-19-5/BI OR 87679-37-6/B I OR 88768-40-5/BI OR 89371-37-9/BI OR 89391-50-4/BI OR 9004-10-8/BI OR 9015-82-1/BI OR 9028-31-3/BI OR 9028-35-7/BI OR 93479-97-1/BI OR 93957-54-1/BI OR 97322-87-7/BI OR 98048-97-6/BI OR 99434-90-9/BI)

L8 2 SEA FILE=REGISTRY L7 AND PYRIMID?

L9 71 SEA FILE=HCAPLUS L8

L10 1 SEA FILE=REGISTRY INSULIN/CN

L11 7 SEA FILE=REGISTRY (TROGLITAZONE/CN OR "TROGLITAZONE DIHYDRATE"/CN OR "TROGLITAZONE GLUCURONIDE"/CN OR "TROGLITAZONE METABOLITE A"/CN OR "TROGLITAZONE METABOLITE B"/CN OR "TROGLITAZONE QUINONE"/CN OR "TROGLITAZONE SULFATE"/CN OR "TROGLITAZONE SULFATE ESTER"/CN)

L12 3 SEA FILE=REGISTRY (ROSIGLITAZONE/CN OR "ROSIGLITAZONE MALEATE"/CN OR "ROSIGLITAZONE NITRATE"/CN)

L13 4 SEA FILE=REGISTRY (PIOGLITAZONE/CN OR "PIOGLITAZONE HYDROCHLORIDE"/CN OR "PIOGLITAZONE N-OXIDE"/CN OR "PIOGLITAZONE NITRATE"/CN)
L14 1 SEA FILE=REGISTRY "MCC 555"/CN
L15 1 SEA FILE=REGISTRY GLIMEPIRIDE/CN
L16 6 SEA FILE=REGISTRY (GLIBENCLAMIDE/CN OR "GLIBENCLAMIDE SODIUM"/CN OR "GLIBENCLAMIDE-.BETA.-CYCLODEXTRIN COMPLEX (1:2)"/CN OR "GLIBENCLAMIDE-GLUCOSE MIXTURE"/CN OR "GLIBENCLAMIDE-PHENFORMIN HYDROCHLORIDE MIXT."/CN OR "GLIBENCLAMIDE-PHENFORMIN MIXT."/CN)
L17 3 SEA FILE=REGISTRY (GLICLAZIDE/CN OR "GLICLAZIDE-.BETA.-CYCLODEXTRIN INCLUSION COMPLEX (1:1)"/CN OR "GLICLAZIDE-TRIMETAZIDINE 1:1 SALT"/CN)
L18 2 SEA FILE=REGISTRY (TOLAZAMIDE/CN OR "TOLAZAMIDE COMPD. WITH AMMONIA (1:2)"/CN)
L19 6 SEA FILE=REGISTRY (METFORMIN/CN OR "METFORMIN CLOFIBRATE"/CN OR "METFORMIN HYDROCHLORIDE"/CN OR "METFORMIN OROTATE"/CN OR "METFORMIN PAMOATE"/CN OR "METFORMIN TOLBUTAMIDE SALT"/CN)
L20 2 SEA FILE=REGISTRY (ACARBOSE/CN OR "ACARBOSE 7-KINASE"/CN)
L21 1 SEA FILE=REGISTRY REPAGLINIDE/CN
L23 146762 SEA FILE=HCAPLUS L10 OR INSULIN
L24 1146 SEA FILE=HCAPLUS L11 OR TROGLITAZONE
L25 621 SEA FILE=HCAPLUS L12 OR ROSIGLITAZONE?
L26 576 SEA FILE=HCAPLUS L13 OR PIOGLITAZONE?
L27 32 SEA FILE=HCAPLUS L14 OR MCC(W)555
L28 216 SEA FILE=HCAPLUS L15 OR GLIMEPIRIDE?
L29 4718 SEA FILE=HCAPLUS L16 OR GLIBENCLAMIDE?
L30 515 SEA FILE=HCAPLUS L17 OR GLICLAZIDE?
L31 316 SEA FILE=HCAPLUS L18 OR TOLAZAMIDE?
L32 1472 SEA FILE=HCAPLUS L19 OR METFORMIN
L33 799 SEA FILE=HCAPLUS L20 OR ACARBOSE?
L34 184 SEA FILE=HCAPLUS L21 OR REPAGLINIDE?
L36 152411 SEA FILE=HCAPLUS L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34
L37 16 SEA FILE=HCAPLUS L9 AND L36
L38 12 SEA FILE=HCAPLUS L37 AND DIABET?

=> d ibib abs hitrn l38 1-12

L38 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:813924 HCAPLUS
DOCUMENT NUMBER: 137:311200
TITLE: Preparation of 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV
INVENTOR(S): Sulsky, Richard B.; Robl, Jeffrey A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083128	A1	20021024	WO 2002-US10936	20020405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG



PRIORITY APPLN. INFO.:

US 2001-283438P P 20010412

OTHER SOURCE(S):

MARPAT 137:311200

GI



AB The invention describes dipeptidyl peptidase IV (DP 4) inhibiting compds. I [n is 0 or 1; X is H or CN; Y is N, NH or O; Z is CH₂ when Y is O or NH, with Y-Z forming a single bond, and Z is CH when Y is N, with Y-Z forming a double bond; R₁-R₄ = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, bicycloalkyl, bicycloalkylalkyl, alkylthioalkyl, arylalkylthioalkyl, cycloalkenyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl or cycloheteroalkylalkyl, which may be substituted; R₁ may combine with R₃ or R₄ to form a ring (CR₅R₆)₂₋₆ or (CR₇R₈)₃₋₆, resp., where R₅-R₈ = H, OH, alkoxy, alkyl, aryl, etc.] and their pharmaceutically-acceptable salts or prodrug esters. A method is also provided for treating **diabetes** and related diseases, employing a DP 4 inhibitor I, optionally in combination with other therapeutic agents, including an antidiabetic, hypolipidemic, or anti-obesity agent. Thus, coupling of sultam-protected 1,2-pyrazoline-3-carboxamide with (S)-N-(tert-butoxycarbonyl)cyclohexylglycine (HOAt, Et₃N, and EDAC in CH₂Cl₂), followed by sultam cleavage with methanolic ammonia, amide conversion to nitrile using imidazole, and deprotection, afforded II.TFA.

IT 657-24-9, **Metformin** 9004-10-8, **Insulin**
 , biological studies 10238-21-8, **Glyburide** 21187-98-4,
Gliclazide 56180-94-0, **Acarbose**
 93479-97-1, **Glimepiride** 97322-87-7,
Troglitazone 111025-46-8, **Pioglitazone**
 122320-73-4, **Rosiglitazone** 135062-02-1,
Repaglinide

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antidiabetic agent; prepn. of oxazoline and pyrazoline-based
 inhibitors of dipeptidyl peptidase IV)

IT 287714-41-4, Rosuvastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipid modulating agent; prepn. of oxazoline and pyrazoline-based
inhibitors of dipeptidyl peptidase IV)REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:813874 HCAPLUS

DOCUMENT NUMBER: 137:311199

TITLE: Amino acid complexes of C-aryl glucosides for
treatment of diabetes

INVENTOR(S): Gougoutas, Jack Z.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083066	A2	20021024	WO 2002-US11066	20020408
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-283097P P 20010411

OTHER SOURCE(S): MARPAT 137:311199

GI



AB Cryst. complexes are obtained from 1:1 or 2:1 mixts. of either the (D) or (L) enantiomer of natural amino acids and compds. of formula I [R1, R2, R2a = H, OH, OR5, alkyl, OCHF2, OCF3, SR5a, halogen; R3, R4 = H, OH, OR5b, alkyl, cycloalkyl, CF3, OCHF2, OCF3, halogen, CONR6R6a, CO2R5c, CO2H, COR6b, CH(OH)R6c, CH(OR5d)R6d, CN, NHCOR5e, NHSO2R5f, NHSO2-aryl, SR5g, SOR5h, SO2R5i, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms (N, O, S, SO, and/or SO2), or R3 and R4 together with the carbons to which they are attached form an annelated


five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring; R5, R5a-R5i are independently alkyl; R6, R6a-R6d are independently H, alkyl, aryl, alkylaryl or cycloalkyl, or NR6R6a form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring]. A method is also provided for treating **diabetes** and related diseases employing an SGLT2 (sodium dependent glucose transporters found in the intestine and kidney) inhibiting amt. of the above complex alone or in combination with another antidiabetic agent or other therapeutic agent. Thus, I (R1 = 4-Me, R4 = 4-OCHF2, R2, R2a, R3 = H) was prepd. by a multistep procedure starting from o-toluic acid, anisole, 2,3,4,6-tetra-O-benzyl-.beta.-D-glucolactone, and CHF2Cl and treated with L-phenylalanine to form the cryst. 1:1 complex.

IT 657-24-9, Metformin 9004-10-8, Insulin
, biological studies 10238-21-8, Glyburide 21187-98-4,
Gliclazide 56180-94-0, Acarbose
93479-97-1, Glimepiride 97322-87-7,
Troglitazone 111025-46-8, Pioglitazone
122320-73-4, Rosiglitazone 135062-02-1,
Repaglinide 287714-41-4, Rosuvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of amino acid/C-aryl glucoside complexes for treatment of
diabetes and related diseases)

L38 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:736927 HCAPLUS
DOCUMENT NUMBER: 137:247879
TITLE: Preparation of antidiabetic agents C-aryl glucoside as
human SGLT2 inhibitors
INVENTOR(S): Ellsworth, Bruce; Washburn, William N.; Sher, Philip
M.; Wu, Gang; Meng, Wei
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S.
6,414,126.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002137903	A1	20020926	US 2002-151436	20020520
US 6414126	B1	20020702	US 2000-679027	20001004
PRIORITY APPLN. INFO.:			US 1999-158773P	P 19991012
			US 2000-194615P	P 20000405
			US 2000-679027	A2 20001004

GI



I

AB An SGLT2 inhibiting compd. is provided having the formula I method is also provided for treating **diabetes** and related diseases employing an SGLT2 inhibiting amt. of the above compd. alone or in combination with another antidiabetic agent or other therapeutic agent (no data). 1A pharmaceutical combination comprising an SGLT2 inhibitor compd. and an antidiabetic agent other than an SGLT2 inhibitor, for treating the complications of **diabetes**, an anti-obesity agent, an antihypertensive agent, an antiplatelet agent, an antiatherosclerotic agent, and/or a lipid-lowering agent (no data). A method for treating or delaying the progression or onset of **diabetes**, **diabetic** retinopathy, **diabetic** neuropathy, **diabetic** nephropathy, delayed wound healing, **insulin** resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, **diabetic** complications, atherosclerosis or hypertension, or for increasing high d. lipoprotein levels, which comprises administering to a mammalian species in need of treatment a therapeutically effective amt. of a compd (no data).

IT 657-24-9, **Metformin** 9004-10-8, **Insulin**, biological studies 10238-21-8, Glyburide 21187-98-4, Gliclazide 56180-94-0, **Acarbose** 93479-97-1, **Glimepiride** 97322-87-7, **Troglitazone** 111025-46-8, **Pioglitazone** 122320-73-4, **Rosiglitazone** 135062-02-1, **Repaglinide** 287714-41-4, Rosuvastatin
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of antidiabetic agents C-aryl glucosides as human SGLT2 inhibitors)

L38 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:637483 HCAPLUS

DOCUMENT NUMBER: 137:185311

TITLE: Preparation of 2-aryloxy-2-arylalkanoic acids for **diabetes** and lipid disorders

INVENTOR(S): Adams, Alan D.; Jones, A. Brian; Berger, Joel P.; Dropinski, James F.; Elbrecht, Alexander; Liu, Kun; Macnaul, Karen Lamb; Shi, Guo-qiang; Von, Langen Derek J.; Zhou, Gaochao

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 157 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064094	A2	20020822	WO 2002-US4680	20020205
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,			

Searched by M. Smith

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.:

US 2001-267809P P 20010209

OTHER SOURCE(S):

MARPAT 137:185311

GI



AB Title compds. I [R1 = halo, alkyl, alkoxy; R2 = alkyl, alicyclic; R3 = alkyl, aryl, alicyclic, heterocycle, etc.; R4 = H, OH, alkoxy, aryloxy, halo or R3-4 may be joined together to yield 5- or 6-membered heterocycle; R5 = H, halo; R6 = H, halo, CH3, CF3; Ar1 = Ph, thienyl, thiazolyl, oxazolyl, pyridyl; X = O, S; Z = COOH, tetrazole, carboxamide] were prepd. For instance, 2,4-dipropylresorcinol was converted to 2,4-dihydroxy-3,5-dipropyl-.alpha.,.alpha.,.alpha.-trifluoroacetophenone (CH2Cl2, TFAA, AlCl3) and subsequently treated with i. hydroxylamine.bul.HCl, MeOH, reflux; ii. Ac2O; iii. pyridine, reflux which afforded 5,7-dipropyl-6-hydroxy-3-trifluoromethyl-1,2-benzisoxazole. The benzisoxazole was reacted with Me 2-bromo-2-phenylacetate (DMF, Cs2CO3) and the product sapond. to give II. I are potent agonists of the peroxisome proliferator activated receptor and are useful in the treatment of non-insulin dependent **diabetes** mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR-.alpha. and/or PPAR-.gamma. mediated diseases.

IT 657-24-9, Metformin 56180-94-0,
Acarbose 97322-87-7, Troglitazone
111025-46-8, Pioglitazone 122320-73-4,
Rosiglitazone 147098-20-2, ZD-4522 161600-01-7
, MCC-555

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; prepn. of 2-aryloxy-2-arylalkanoic acids
for **diabetes** and lipid disorders)

IT 9004-10-8, Insulin, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance; prepn. of 2-aryloxy-2-arylalkanoic acids for
diabetes and lipid disorders)

L38 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:594636 HCAPLUS

DOCUMENT NUMBER: 137:135097

TITLE: Acyl sulfamides for treatment of obesity,
diabetes and lipid disorders

INVENTOR(S): Jones, A. Brian; Acton, John J., III

PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060388	A2	20020808	WO 2002-US3119	20020125
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-264955P P 20010130

OTHER SOURCE(S): MARPAT 137:135097

AB A class of acyl sulfamides comprises compds. that are potent ligands for PPAR.gamma. receptors and generally have antagonist or partial agonist activity. The compds. may be useful in the treatment, control or prevention of obesity, non-**insulin** dependent **diabetes** mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, inflammation, and other PPAR.gamma. receptor-mediated diseases, disorders and conditions, alone or in combination with one or more other compds. Other compds. are selected from **insulin** sensitizers, **insulin** or **insulin** mimetics, sulfonylureas, .alpha.-glucosidase inhibitors, cholesterol lowering agents, PPAR.delta. agonists, antiobesity compds., an ileal bile acid transporter inhibitor, and agents intended for use in inflammatory conditions such as aspirin, nonsteroidal anti-inflammatory drugs, glucocorticoids, azulfidine, and cyclooxygenase-2 selective inhibitors.

IT 657-24-9, Metformin 56180-94-0,
 Acarbose 97322-87-7D, Troglitazone, derivs.
 111025-46-8, Pioglitazone 122320-73-4,
 Rosiglitazone 147098-20-2, ZD-4522 161600-01-7
 , MCC-555

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (acyl sulfamides and other drugs for treatment of metabolic disorders mediated by PPAR.gamma. receptors)

IT 9004-10-8, **Insulin**, biological studies

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mimetics and sensitizers of and resistance to; acyl sulfamides and other drugs for treatment of metabolic disorders mediated by PPAR.gamma. receptors)

L38 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:575765 HCAPLUS

DOCUMENT NUMBER: 137:140435



TITLE: Benzopyrancarboxylic acid derivatives with PPAR agonist activity for the treatment of **diabetes** and lipid disorders, and their preparation, pharmaceutical compositions, and use

INVENTOR(S): Sahoo, Soumya P.; Koyama, Hiroo; Miller, Daniel J.;
Boueres, Julia K.; Desai, Ranjit C.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002103242	A1	20020801	US 2001-21667	20011029
WO 2002060434	A2	20020808	WO 2001-US49501	20011026

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-244698P P 20001031
OTHER SOURCE(S): MARPAT 137:140435
GI



AB A class of benzopyrancarboxylic acid derivs. is disclosed, which comprises compds. that are potent agonists (no data) of peroxisome proliferator activated receptors (PPAR) alpha and/or gamma, and are therefore useful in the treatment, control, or prevention of non-**insulin** dependent **diabetes** mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions. In particular, compds. I and their pharmaceutically acceptable salts and/or

prodrugs are disclosed [wherein: Z = CH₂, CO; R₁ = H, OH, halo, (un)substituted alk(en/yn)yl, alk(en/yn)yoxy, or aryl; or R₁ forms (un)substituted cyclopropane fusion to adjacent C atom; X, Y = O, S, SO, SO₂, CH₂, (un)substituted NH; n = 1-6; R₄ = (un)substituted benzoheterocyclyl, cycloalkyl, heterocyclyl, cycloalkyloxy, halo, OH or derivs., alk(en/yn)yl, alk(en/yn)yoxy, or aryl, etc.; other R groups = H, halo, OH, (un)substituted alk(en/yn)yl, alk(en/yn)yoxy, aryl, aryloxy, aroyl, etc.; or R₃R₄ or R₄R₅ = (un)substituted 5- or 6-membered heterocyclic ring]. A list of 29 compds. is claimed, and their prepn. is described. For example, Et 7-hydroxy-4-oxo-4H-chromene-2-carboxylate underwent a sequence of: (1) complete hydrogenation of the enone (98%), (2) etherification of the alc. with PhCH₂O(CH₂)₃Br (66%), (3) alpha ethylation of the ester (70%), (4) hydrogenolytic debenzylation (100%), (5) conversion of the resultant alc. to a bromide (96%), (6) etherification of the bromide with 3-(trifluoromethyl)-7-propyl-6-hydroxybenz[4,5]isoxazole (85%), and (7) alk. hydrolysis (100%), to give title compd. II. PPAR binding assays using human recombinant PPAR are described without data. Co-administration of compds. I with a variety of other drug categories, including a no. of specific drugs, is claimed.

IT 9004-10-8, **Insulin**, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (resistance, treatment of; prepn. of benzopyrancarboxylic acid derivs. as PPAR agonists for treatment of **diabetes** and lipid disorders)

IT 657-24-9, **Metformin** 9004-10-8D, **Insulin**, mimetics 56180-94-0, **Acarbose** 97322-87-7, **Troglitazone** 111025-46-8, **Pioglitazone** 122320-73-4, **Rosiglitazone** 147098-20-2, ZD-4522 161600-01-7, MCC-555

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapeutic compns. also contg.; prepn. of benzopyrancarboxylic acid derivs. as PPAR agonists for treatment of **diabetes** and lipid disorders)

L38 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:540258 HCAPLUS

DOCUMENT NUMBER: 137:109267

TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors

INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 875,155.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002094977	A1	20020718	US 2001-7407	20011204
US 2002013334	A1	20020131	US 2001-875155	20010606
PRIORITY APPLN. INFO.:			US 2000-211595P	P 20000615
			US 2001-875155	A2 20010606

OTHER SOURCE(S): MARPAT 137:109267

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Title compds. I [X = O, S, SO, SO₂, NR₇; Z = HOCHCH₂CH(OH)CH₂CO₂R₃, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R₁, R₂ = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R₃ = H, alkyl, metal ion; R₄ = H, halo, CF₃, etc.; R₇ = H, alkyl, aryl, alkanoyl, aroyl, alkoxy carbonyl, etc.; R₉, R₁₀ = H, alkyl], were prepd. as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis (no data). E.g., a multistep synthesis of II is reported.
- IT 657-24-9, **Metformin** 10238-21-8, Glyburide 21187-98-4, **Gliclazide** 56180-94-0, **Acarbose** 93479-97-1, **Glimepiride** 97322-87-7, **Troglitazone** 111025-46-8, **Pioglitazone** 122320-73-4, **Rosiglitazone** 135062-02-1, **Repaglinide** 287714-41-4, Rosuvastatin
- RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministered agents; prepn. of benzoxepinopyridines as HMG-CoA reductase inhibitors for the treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)
- IT 9004-10-8P, **Insulin**, preparation
- RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (sensitizers, resistance, coadministered agents; prepn. of benzoxepinopyridines as HMG-CoA reductase inhibitors for the treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

L38 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:240561 HCAPLUS

DOCUMENT NUMBER: 136:257242

TITLE: Statins (HMG-CoA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent

INVENTOR(S): Mach, Francois

PATENT ASSIGNEE(S): Novimmune S.A., Switz.

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024194	A2	20020328	WO 2001-EP11485	20010919
WO 2002024194	C2	20020919		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,

UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002010521 A5 20020402 AU 2002-10521 20010919

PRIORITY APPLN. INFO.: US 2000-664871 A 20000919

WO 2001-EP11485 W 20010919

AB The present invention relates to methods of causing MHC-class II or CD40 mediated immunomodulation, immunosuppression and anti-inflammatory action, in a subject suffering from or susceptible of suffering from a condition involving inappropriate immune response, which comprises administering to the subject at least one statin, or a functionally or structurally equiv. mol., in an amt. effective to modulate MHC class II or CD40 expression in the subject. The present invention provides a new class of agents that reduce or repress T-lymphocyte activation mediated by class II or CD40 expression and consequently are capable of acting as immunomodulators and antiinflammatory agents.

IT 287714-41-4, Rosuvastatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(statins (HMG-CoA reductase inhibitors) as immunosuppressor and antiinflammatory agents that modulate MHC-class II or CD40 expression inducible by interferon .gamma. and T-lymphocyte activation)

L38 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:157564 HCAPLUS

DOCUMENT NUMBER: 136:205424

TITLE: Combinations of **insulin** secretion enhancer, HMG-CoA reductase inhibitors and acetylcholinesterase inhibitors

INVENTOR(S): Allison, Malcolm; Gatlin, Marjorie Regan

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002015892	A2	20020228	WO 2001-EP9586	20010820
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

AU 2002014952 A5 20020304 AU 2002-14952 20010820

PRIORITY APPLN. INFO.: US 2000-643642 A 20000822

WO 2001-EP9586 W 20010820

AB The present invention relates to a combination, esp. a pharmaceutical compn., comprising (a) an **insulin** secretion enhancer or a pharmaceutically acceptable salt thereof and (b) at least one of the active ingredients selected from the group consisting of (i) HMG-Co-A

reductase inhibitors or a pharmaceutically acceptable salt thereof; and
(ii) ACE inhibitors or a pharmaceutically acceptable salt thereof; and, in
case of a pharmaceutical compn., a pharmaceutically acceptable carrier.
Formulations were given as examples, e.g., tablets contg. nateglinide.

IT 9004-10-8, **Insulin**, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(combinations of **insulin** secretion enhancer, HMG-CoA
reductase inhibitors and acetylcholinesterase inhibitors)

IT 1156-19-0, **Tolazamide 10238-21-8,**

Glibenclamide 21187-98-4, Gliclazide

93479-97-1, Glimepiride 135062-02-1,

Repaglinide 287714-41-4, Rosuvastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of **insulin** secretion enhancer, HMG-CoA
reductase inhibitors and acetylcholinesterase inhibitors)

L38 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:90008 HCAPLUS

DOCUMENT NUMBER: 136:151071

TITLE: Preparation of N-substituted indoles for treating
diabetes

INVENTOR(S): Acton, John J., III; Black, Regina Marie; Jones,
Anthony Brian; Wood, Harold Blair

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008188	A1	20020131	WO 2001-US22979	20010720
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2002042441 A1 20020411 US 2001-912961 20010725

PRIORITY APPLN. INFO.: US 2000-220778P P 20000725

OTHER SOURCE(S): MARPAT 136:151071

GI



AB The title indoles having aryloxyacetic acid substituents [I; R1 = Me, optionally substituted with 1-3 F atoms; R2-R4 = H, halo, alkyl, etc.; R5, R6 = H, F, OH, alkyl; and R5 and R6 groups that are on the same carbon atom optionally may be joined to form a cyclopropyl group; R7, R8 = H, F, alkyl; or CR7R8 may form cycloalkyl; R9 = H, alkyl; Ar1 = (un)substituted Ph, naphthyl, pyridyl, quinolyl; X = CO, SO2, CH2, CHMe, CMe2, CF2, cyclopropylidene; Y = O, S; n = 0-5] which are agonists or partial agonists of PPAR gamma, and are useful in the treatment, control or prevention of non-insulin dependent **diabetes** mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR mediated diseases, disorders and conditions, were prepd. E.g., a multi-step synthesis of (2S)-II was given.

IT 657-24-9, Metformin 56180-94-0,
Acarbose 97322-87-7, Troglitazone
111025-46-8, Pioglitazone 122320-73-4,
Rosiglitazone 147098-20-2, ZD-4522 161600-01-7
, MCC-555

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of N-substituted indoles for treating **diabetes**)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:617987 HCAPLUS

DOCUMENT NUMBER: 135:180757

TITLE: Preparation of 1,2-benzoxazolyloxyacetic acids and
analogs as PPAR agonists for treatment of
diabetes and lipid disorders



INVENTOR(S): Liu, Kun; Xu, Libo; Jones, A. Brian

PATENT ASSIGNEE(S): Merck + Co. Inc., USA

SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060807	A1	20010823	WO 2001-US4636	20010214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-183593P P 20000218
 OTHER SOURCE(S): MARPAT 135:180757
 GI



AB The title compds. (I) [wherein R1 and R2 = independently H, F, (halo)alkyl, (halo)alkenyl, (halo)alkynyl; or R1 and R2 may form a cycloalkyl group; R3 and R4 = independently (fluoro)alkyl, (fluoro)alkenyl, (fluoro)alkynyl, or Cl; X = N or CR; Y = O, S, nor NR; Z = O or S; R = independently H or optionally fluoro- or alkoxy-substituted (cyclo)alkyl(oxy), alkenyl(oxy), or alkynyl(oxy); R5 = H or (un)substituted alkyl, alkenyl, alkynyl, (hetero)aryl(oxy), heterocyclyl(oxy), etc.; and pharmaceutically acceptable salts and prodrugs thereof] were prepd. For example, 2,4-dihydroxy-3,5-dipropyl-1',1',1'-trifluoroacetophenone oxime was acetylated and then treated with pyridine and TEA to give 5,7-dipropyl-6-hydroxy-3-trifluoromethyl-1,2-benzisoxazole. Etherification with Me .alpha.-bromoisobutyrate in the presence of Cs₂CO₃ in DMF, followed by sapon., afforded the 1,2-benzoxazolyloxyacetic acid (II). I are potent agonists of peroxisome proliferator activated receptor (PPAR) .alpha. and/or .gamma. and are useful in the treatment, control, or prevention of non-insulin dependent **diabetes** mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia,

atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR.alpha. and/or .gamma. mediated diseases, disorders, and conditions (no data).

IT 657-24-9, Metformin 9004-10-8, Insulin
 , biological studies 9004-10-8D, Insulin, mimetics,
 biological studies 56180-94-0, Acarbose
 97322-87-7, Troglitazone 111025-46-8,
 Pioglitazone 122320-73-4, Rosiglitazone
 147098-20-2, ZD-4522 161600-01-7, MCC-
 555

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(coadministration with; prepn. of benzisoxazolyloxyacetic acid PPAR agonists via cyclization of dihydroxyacetophenone oximes for treatment of **diabetes** and lipid disorders)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:553418 HCAPLUS

DOCUMENT NUMBER: 133:144931

TITLE: Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of **diabetic** neuropathy

INVENTOR(S): Cameron, Norman Eugene; Cotter, Mary Anne

PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK; University Court of the University of Aberdeen

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045818	A1	20000810	WO 2000-GB280	20000201
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BE, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000007996	A	20011030	BR 2000-7996	20000201
EP 1150678	A1	20011107	EP 2000-901744	20000201
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002536332	T2	20021029	JP 2000-596938	20000201
NO 2001003812	A	20011002	NO 2001-3812	20010803
PRIORITY APPLN. INFO.:			GB 1999-2591	A 19990206
			GB 1999-2594	A 19990206
			WO 2000-GB280	W 20000201

AB The invention relates to a new use of a statin drug in the improvement of **diabetic** neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering **diabetes**, in

particular to pharmaceutical combinations of the statin drug and other agents known to improve **diabetic** neuropathy such as an aldose reductase inhibitor, an angiotensin converting enzyme inhibitor, or an angiotensin II antagonist, which combinations are useful in the prevention and treatment of the complications of **diabetes**.

IT 657-24-9, Metformin 1156-19-0,
Tolazamide 9004-10-8, Insulin, biological
studies 10238-21-8, Glibenclamide 21187-98-4
, Gliclazide 56180-94-0, Acarbose
93479-97-1, Glimepiride 97322-87-7,
Troglitazone 111025-46-8, Pioglitazone
122320-73-4, Rosiglitazone 135062-02-1,
Repaglinide 147098-20-2 161600-01-7,
MCC-555 287714-41-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(HMG-CoA reductase inhibitors for treatment of **diabetic** neuropathy, and combinations with other agents)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT